First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with HER2 amplification (HER2amp+), RAS wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.
Open Access
- 1 August 2023
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (Supplement) , 53
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company Ltd., Tokyo, Japan